Prosthetic gene networks as an alternative to standard pharmacotherapies for metabolic disorders

Current Opinion in Biotechnology

Volumn 35, Issue , 2015, Pages 37-45

  Heng, Boon Chin ^a,b   Aubel, Dominique ^c   Fussenegger, Martin ^b,d  

^a SUNWAY UNIVERSITY   (Malaysia)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITÉ LYON 1   (France)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE CONTROL; GENES; INTERFACE STATES; METABOLISM; PROSTHETICS;

CLINICAL THERAPY; DISEASE STATE; GLOBAL EPIDEMIC; METABOLIC DISORDERS; PHARMACOTHERAPIES; PROSTHETIC NETWORKS; SYNTHETIC BIOLOGY; TYPE-2 DIABETES;

GENE THERAPY;

ATRIAL NATRIURETIC FACTOR; DOPAMINE; GLUCOSE; GUANABENZ; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PRAMLINTIDE;

ANP GENE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL TRANSPLANTATION; DEVICE SAFETY; DIABETIC KETOACIDOSIS; DOPAMINE BLOOD LEVEL; ELECTROMAGNETIC RADIATION; GENE EXPRESSION; GLP 1 GENE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERURICEMIA; INSULIN RELEASE; LSR GENE; MEDICAL DEVICE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OPTOGENETICS; PROSTHETIC GENE NETWORK; QUALITY OF LIFE; REPORTER GENE; REVIEW; SEAP GENE; SMUOX GENE; TDAG8 GENE; TRANSGENE; TREATMENT RESPONSE; TRPV1 GENE; UPREGULATION; ANIMAL; GENE REGULATORY NETWORK; KETOACIDOSIS; METABOLIC SYNDROME X; METABOLISM;

ANIMALS; DIABETES MELLITUS, TYPE 2; GENE REGULATORY NETWORKS; HUMANS; KETOSIS; METABOLIC SYNDROME X; OBESITY;

EID: 84922422820     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2015.01.010     Document Type: Review

References (57)

1. Wang Y.H., Wei K.Y., Smolke C.D. Synthetic biology: advancing the design of diverse genetic systems. Annu Rev Chem Biomol Eng 2013, 4:69-102.
2. Lim W.A., Lee C.M., Tang C. Design principles of regulatory networks: searching for the molecular algorithms of the cell. Mol Cell 2013, 49:202-212.
3. Brophy J.A., Voigt C.A. Principles of genetic circuit design. Nat Methods 2014, 11:508-520.
4. Singh V. Recent advancements in synthetic biology: current status and challenges. Gene 2014, 535:1-11.
5. Weber W., Fussenegger M. Molecular diversity - the toolbox for synthetic gene switches and networks. Curr Opin Chem Biol 2011, 15:414-420.
6. Endo K., Hayashi K., Inoue T., Saito H. A versatile cis-acting inverter module for synthetic translational switches. Nat Commun 2013, 4:2393.
7. Minaba M., Kato Y. High-yield, zero-leakage expression system with a translational switch using site-specific unnatural amino Acid incorporation. Appl Environ Microbiol 2014, 80:1718-1725.
8. Rhodius V.A., Segall-Shapiro T.H., Sharon B.D., Ghodasara A., Orlova E., Tabakh H., Burkhardt D.H., Clancy K., Peterson T.C., Gross C.A., Voigt C.A. Design of orthogonal genetic switches based on a crosstalk map of σs, anti-σs, and promoters. Mol Syst Biol 2013, 9:702.
9. Shi C., Zhou T., Yuan Z. Functional tunability of biological circuits from additional toggle switches. IET Syst Biol 2013, 7:126-134.
10. Chen S., Zhang H., Shi H., Ji W., Feng J., Gong Y., Yang Z., Ouyang Q. Automated design of genetic toggle switches with predetermined bistability. ACS Synth Biol 2012, 1:284-290.
11. Ryback B.M., Odoni D.I., van Heck R.G., van Nuland Y., Hesselman M.C., Martins Dos Santos V.A., van Passel M.W., Hugenholtz F. Design and analysis of a tunable synchronized oscillator. J Biol Eng 2013, 7:26.
12. Lomnitz J.G., Savageau M.A. Strategy revealing phenotypic differences among synthetic oscillator designs. ACS Synth Biol 2014, 3:686-701.
13. Hellen E.H., Dana S.K., Zhurov B., Volkov E. Electronic implementation of a repressilator with quorum sensing feedback. PLOS ONE 2013, 8:e62997.
14. Chang Y.C., Lin C.L., Jennawasin T. Design of synthetic genetic oscillators using evolutionary optimization. Evol Bioinform Online 2013, 9:137-150.
15. Osella M., Lagomarsino M.C. Growth-rate-dependent dynamics of a bacterial genetic oscillator. Phys Rev E Stat Nonlin Soft Matter Phys 2013, 87:012726.
16. Padirac A., Fujii T., Estévez-Torres A., Rondelez Y. Spatial waves in synthetic biochemical networks. J Am Chem Soc 2013, 135:14586-14592.
17. Potapov I., Zhurov B., Volkov E. 'Quorum sensing' generated multistability and chaos in a synthetic genetic oscillator. Chaos 2012, 22:023117.
18. Wang B., Barahona M., Buck M. A modular cell-based biosensor using engineered genetic logic circuits to detect and integrate multiple environmental signals. Biosens Bioelectron 2013, 40:368-376.
19. Davidson E.A., Basu A.S., Bayer T.S. Programming microbes using pulse width modulation of optical signals. J Mol Biol 2013, 425:4161-4166.
20. Häkkinen A., Tran H., Yli-Harja O., Ribeiro A.S. Effects of rate-limiting steps in transcription initiation on genetic filter motifs. PLOS ONE 2013, 8:e70439.
21. Greber D., Fussenegger M. An engineered mammalian band-pass network. Nucleic Acids Res 2010, 38:e174.
22. Sohka T., Heins R.A., Phelan R.M., Greisler J.M., Townsend C.A., Ostermeier M. An externally tunable bacterial band-pass filter. Proc Natl Acad Sci U S A 2009, 106:10135-10140.
23. Muranaka N., Yokobayashi Y. A synthetic riboswitch with chemical band-pass response. Chem Commun (Camb) 2010, 46:6825-6827.
24. Sohka T., Heins R.A., Ostermeier M. Morphogen-defined patterning of Escherichia coli enabled by an externally tunable band-pass filter. J Biol Eng 2009, 3:10.
25. Prindle A., Selimkhanov J., Li H., Razinkov I., Tsimring L.S., Hasty J. Rapid and tunable post-translational coupling of genetic circuits. Nature 2014, 508:387-391.
26. Bacchus W., Fussenegger M. Engineering of synthetic intercellular communication systems. Metab Eng 2013, 16:33-41.
27. Hoffman-Sommer M., Supady A., Klipp E. Cell-to-cell communication circuits: quantitative analysis of synthetic logic gates. Front Physiol 2012, 3:287.
28. Chuang J.S. Engineering multicellular traits in synthetic microbial populations. Curr Opin Chem Biol 2012, 16:370-378.
29. Bacchus W., Lang M., El-Baba M.D., Weber W., Stelling J., Fussenegger M. Synthetic two-way communication between mammalian cells. Nat Biotechnol 2012, 30:991-996.
30. Bacchus W., Aubel D., Fussenegger M. Biomedically relevant circuit-design strategies in mammalian synthetic biology. Mol Syst Biol 2013, 9:691.
31. Ye H., Aubel D., Fussenegger M. Synthetic mammalian gene circuits for biomedical applications. Curr Opin Chem Biol 2013, 17:910-917.
32. Wu K., Rao C.V. Computational methods in synthetic biology: towards computer-aided part design. Curr Opin Chem Biol 2012, 16:318-322.
33. Lux M.W., Bramlett B.W., Ball D.A., Peccoud J. Genetic design automation: engineering fantasy or scientific renewal?. Trends Biotechnol 2012, 30:120-126.
34. Ye H., Charpin-El Hamri G., Zwicky K., Christen M., Folcher M., Fussenegger M. Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. Proc Natl Acad Sci U S A 2013, 110:141-146.
35. Ye H., Daoud-El Baba M., Peng R.W., Fussenegger M. A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice. Science 2011, 332:1565-1568.
36. Stanley S.A., Gagner J.E., Damanpour S., Yoshida M., Dordick J.S., Friedman J.M. Radio-wave heating of iron oxide nanoparticles can regulate plasma glucose in mice. Science 2012, 336:604-608.
37. Lam D.W., LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes 2012, 19:93-96.
38. Wang X., Chen X., Yang Y. Spatiotemporal control of gene expression by a light-switchable transgene system. Nat Methods 2012, 9:266-269.
39. Ma Z., Du Z., Chen X., Wang X., Yang Y. Fine tuning the LightOn light-switchable transgene expression system. Biochem Biophys Res Commun 2013, 440:419-423.
40. Stanley S.A., Sauer J., Kane R.S., Dordick J.S., Friedman J.M. Remote regulation of glucose homeostasis in mice using genetically encoded nanoparticles. Nat Med 2015, 21:92-98.
41. Folcher M., Oesterle S., Zwicky K., Thekkottil T., Heymoz J., Hohmann M., Christen M., Daoud El-Baba M., Buchmann P., Fussenegger M. Mind-controlled transgene expression by a wireless-powered optogenetic designer cell implant. Nat Commun 2014, 5:5392.
42. Rössger K., Charpin-El Hamri G., Fussenegger M. Reward-based hypertension control by a synthetic brain-dopamine interface. Proc Natl Acad Sci U S A 2013, 110:18150-18155.
43. Singh M. Mood, food, and obesity. Front Psychol 2014, 5:925.
44. Blum K., Chen A.L., Giordano J., Borsten J., Chen T.J., Hauser M., Simpatico T., Femino J., Braverman E.R., Barh D. The addictive brain: all roads lead to dopamine. J Psychoactive Drugs 2012, 44:134-143.
45. Baradaran A., Nasri H., Rafieian-Kopaei M. Oxidative stress and hypertension: possibility of hypertension therapy with antioxidants. J Res Med Sci 2014, 19:358-367.
46. Symonides B., Holas P., Schram M., Sleszycka J., Bogaczewicz A., Gaciong Z. Does the control of negative emotions influence blood pressure control and its variability?. Blood Press 2014, 23:323-329.
47. Kemmer C., Gitzinger M., Daoud-El Baba M., Djonov V., Stelling J., Fussenegger M. Self-sufficient control of urate homeostasis in mice by a synthetic circuit. Nat Biotechnol 2010, 28:355-360.
48. Karis E., Crittenden D.B., Pillinger M.H. Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way street. South Med J 2014, 107:235-241.
49. Takai M., Yamauchi T., Fujita K., Lee S., Ookura M., Kishi S., Urasaki Y., Yoshida A., Iwasaki H., Ueda T. Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndrome. Oncol Lett 2014, 8:1523-1527.
50. Rössger K., Charpin-El-Hamri G., Fussenegger M. A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice. Nat Commun 2013, 4:2825.
51. Pandey R.P., Li T.F., Kim E.H., Yamaguchi T., Park Y.I., Kim J.S., Sohng J.K. Enzymatic synthesis of novel phloretin glucosides. Appl Environ Microbiol 2013, 79:3516-3521.
52. 2 transgene-control device. Mol Cell 2014, 55:397-408.
53. Gosmanov A.R., Gosmanova E.O., Dillard-Cannon E. Management of adult diabetic ketoacidosis. Diabetes Metab Syndr Obes 2014, 7:255-264.
54. Greco S.J., Rameshwar P. Mesenchymal stem cells in drug/gene delivery: implications for cell therapy. Ther Deliv 2012, 3:997-1004.
55. Sanz L., Compte M., Guijarro-Muñoz I., Álvarez-Vallina L. Non-hematopoietic stem cells as factories for in vivo therapeutic protein production. Gene Ther 2012, 19:1-7.
56. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
57. Turner M., Leslie S., Martin N.G., Peschanski M., Rao M., Taylor C.J., Trounson A., Turner D., Yamanaka S., Wilmut I. Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell 2013, 13:382-384.